Arch Biopartners Inc. (ACHFF)
OTCMKTS · Delayed Price · Currency is USD
0.5900
+0.0100 (1.72%)
Jul 28, 2026, 12:36 PM EST
Arch Biopartners Balance Sheet
Financials in millions CAD. Fiscal year is October - September.
Millions CAD. Fiscal year is Oct - Sep.
Assets
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Mar '26 Mar 31, 2026 | Sep '25 Sep 30, 2025 | Sep '24 Sep 30, 2024 | Sep '23 Sep 30, 2023 | Sep '22 Sep 30, 2022 | Sep '21 Sep 30, 2021 |
Cash & Equivalents | 0.44 | 0 | 0 | 0.83 | 0.51 | 0.45 |
Cash & Short-Term Investments | 0.44 | 0 | 0 | 0.83 | 0.51 | 0.45 |
Cash Growth | 4255.02% | -29.23% | -99.64% | 64.17% | 12.96% | -31.43% |
Accounts Receivable | - | - | 0.72 | - | - | 1.85 |
Other Receivables | 0.02 | 0.08 | 0.17 | 0.3 | 0.09 | 0.35 |
Receivables | 0.02 | 0.08 | 0.9 | 0.3 | 0.09 | 2.2 |
Prepaid Expenses | 0.01 | 0.02 | 0.03 | 0.04 | 0.03 | 0.02 |
Total Current Assets | 0.46 | 0.1 | 0.94 | 1.17 | 0.62 | 2.67 |
Total Assets | 0.46 | 0.1 | 0.94 | 1.17 | 0.62 | 2.67 |
Liabilities
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Mar '26 Mar 31, 2026 | Sep '25 Sep 30, 2025 | Sep '24 Sep 30, 2024 | Sep '23 Sep 30, 2023 | Sep '22 Sep 30, 2022 | Sep '21 Sep 30, 2021 |
Accounts Payable | 1.35 | 1.04 | 2.32 | 0.39 | 0.49 | 0.96 |
Accrued Expenses | - | - | 0.04 | 0.17 | 0.19 | 0.42 |
Short-Term Debt | 2.73 | 2.84 | 2.27 | 1.71 | - | 1.8 |
Current Portion of Long-Term Debt | - | - | 0.5 | 2.6 | 2.1 | - |
Current Unearned Revenue | 0.03 | 0.1 | 0.15 | 1.1 | - | - |
Total Current Liabilities | 4.11 | 3.99 | 5.28 | 5.98 | 2.78 | 3.19 |
Long-Term Debt | - | - | - | 0.7 | 2.31 | 3.36 |
Total Liabilities | 4.11 | 3.99 | 5.28 | 6.68 | 5.09 | 6.55 |
Shareholders' Equity
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Mar '26 Mar 31, 2026 | Sep '25 Sep 30, 2025 | Sep '24 Sep 30, 2024 | Sep '23 Sep 30, 2023 | Sep '22 Sep 30, 2022 | Sep '21 Sep 30, 2021 |
Common Stock | 21.88 | 20.35 | 18.25 | 15.88 | 15.55 | 14.76 |
Additional Paid-In Capital | 7.38 | 6.6 | 6.68 | 6.66 | 4.7 | 4.68 |
Retained Earnings | -35.6 | -33.52 | -31.97 | -28.05 | -24.72 | -23.32 |
Comprehensive Income & Other | 2.69 | 2.69 | 2.69 | - | - | - |
Shareholders' Equity | -3.64 | -3.88 | -4.35 | -5.51 | -4.47 | -3.88 |
Total Liabilities & Equity | 0.46 | 0.1 | 0.94 | 1.17 | 0.62 | 2.67 |
Additional Metrics
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Mar '26 Mar 31, 2026 | Sep '25 Sep 30, 2025 | Sep '24 Sep 30, 2024 | Sep '23 Sep 30, 2023 | Sep '22 Sep 30, 2022 | Sep '21 Sep 30, 2021 |
Total Debt | 2.73 | 2.84 | 2.77 | 5.02 | 4.41 | 5.16 |
Net Cash (Debt) | -2.29 | -2.84 | -2.77 | -4.18 | -3.91 | -4.72 |
Net Cash Growth | - | - | - | - | - | - |
Net Cash Per Share | -0.03 | -0.04 | -0.04 | -0.07 | -0.06 | -0.08 |
Filing Date Shares Outstanding | 67.93 | 66.93 | 64.94 | 62.76 | 62.4 | 61.36 |
Total Common Shares Outstanding | 67.73 | 66.11 | 64.65 | 62.6 | 62.33 | 61.96 |
Working Capital | -3.64 | -3.88 | -4.35 | -4.81 | -2.16 | -0.52 |
Book Value Per Share | -0.05 | -0.06 | -0.07 | -0.09 | -0.07 | -0.06 |
Tangible Book Value | -3.64 | -3.88 | -4.35 | -5.51 | -4.47 | -3.88 |
Tangible Book Value Per Share | -0.05 | -0.06 | -0.07 | -0.09 | -0.07 | -0.06 |